Last reviewed 2026-04-23 · How we verify

Sertraline/omega-3

Sertraline is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in the brain, while omega-3 fatty acids have anti-inflammatory properties.

Sertraline is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in the brain, while omega-3 fatty acids have anti-inflammatory properties. Used for Major depressive disorder, Generalized anxiety disorder.

At a glance

Mechanism of action

Sertraline works by blocking the reabsorption of serotonin in the brain, leading to increased levels of this neurotransmitter. Omega-3 fatty acids, particularly EPA and DHA, have been shown to reduce inflammation and may have a role in improving mood and cognitive function.

Approved indications

• Major depressive disorder
• Generalized anxiety disorder

Common side effects

• Nausea
• Headache
• Diarrhea
• Insomnia
• Dry mouth

Key clinical trials

• Effect of Combined Antioxidant Therapy on Oxidative Stress Markers and Inflammatory Cytokines in Patients With Tinnitus (PHASE2)
• Omega-3 for Depression and Other Cardiac Risk Factors - 2 (PHASE2)
• Omega-3 Fatty Acids to Improve Depression and Reduce Cardiovascular Risk Factors (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Sertraline/omega-3 CI brief — competitive landscape report
• Sertraline/omega-3 updates RSS · CI watch RSS
• Washington University School of Medicine portfolio CI